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SUMMARY
Introduction/Objective The objective of the study was to investigate whether there are differences in 
therapeutic effect between initial treatments of chronic periodontitis [scaling and root planning (SRP)] 
alone and SRP in conjunction with injectable platelet-rich fibrin (I-PRF) application, comparing clinical 
parameters after three months.
Methods Twenty-four patients with chronic periodontitis who had at least two sites with probing pocket 
depth (PPD) ≥ 5 mm on contralateral side participated in the study. Using a split-mouth design, the pa-
tients were treated with SRP + I-PRF (study group) or SRP only (control group). The clinical parameters, 
clinical attachment level (CAL), gingival margin level (GML), PPD, bleeding on probing, and plaque index, 
were recorded on both sides.
Results Compared to baseline, both treatment modalities demonstrated an improvement in investigated 
clinical parameters. The mean value of CAL was reduced from 1.97 ± 0.75 (0.25–3.31) to 1.07 ± 0.44 
(0.12–1.78) in the study group, whereas it decreased from 1.81 ± 0.66 (0.42–2.96) to 1.48 ± 0.55 (0.22–2.30) 
in the control group. Similarly, the corresponding values for GML and PPD showed statistically significant 
difference between the groups (p = 0.040 and p = 0.006, respectively).
Conclusion Regardless the limited number of patients in the study, initial periodontal therapy in conjunc-
tion with injectable platelet-rich fibrin proved to display significant improvement in all clinical parameters 
compared to initial periodontal therapy alone.
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INTRODUCTION
Periodontitis is a chronic multifactorial disease, 
characterized by the progressive destruction 
of periodontal supporting tissues. Periodon-
titis presents an inflammation developed by 
disorders of the host immune response to the 
infections caused by periodontopathogens [1]. 
Chronic periodontitis (CP) represents a form 
of destructive periodontal disease that is gener-
ally characterized by slow progression [2]. The 
World Workshop on the Classification of Peri-
odontal and Peri-implant Disease and Condi-
tion in 2017 agreed that the disease previously 
described as “chronic” or “aggressive” would 
be grouped under a category “periodontitis” 
[3]. Periodontitis was regarded as the sixth 
most prevalent disease globally in 2010 and it 
affected approximately 50% of the adult popu-
lation worldwide in 2014 [4]. Due to its high 
prevalence it is essential to constantly upgrade 
periodontal therapy.
The principal goal of the periodontal ther-
apy is to restrain active inflammation during 
the disease and possibly provide support for 
the reconstruction of periodontal tissue defects 
[5]. Initial periodontal therapy, scaling and 
root planning (SRP) is not frequently resolute 
at repairing disease-related defects [6, 7]. The 
periodontal wound healing after SRP usually 
induces the development of a long junctional 
epithelium, which is responsible for frequent 
recurrence of a periodontal pocket [8]. To en-
hance the process of regeneration, the adjunc-
tive therapeutic procedures have been added 
to the conventional therapy since the end of 
the last century.
Platelets have been applied in dentistry over 
the past three decades. These autologous re-
generative tools are concentrated suspensions 
of supra-physiological amount of growth factors 
(GFs) and, when applied locally, can induce soft 
and hard tissue regeneration [8]. Platelets are im-
portant reservoirs of various GFs and cytokines, 
which are vital in wound repair and homeosta-
sis [8]. The periodontal wound healing process 
implies a series of cell-to-cell interactions and 
molecular signals that are primarily mediated 
by cytokines and GFs. GFs control enhancing 
collagen production, cell proliferation and differ-
entiation, as well as blood vessel formation [9].
Platelet concentrates have advanced from 
the first generation, platelet-rich plasma (PRP) 
to the second generation, platelet-rich fibrin 
(PRF). PRF, developed by Choukroun et al. 
[10], enables a scaffold enriched with platelets 
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and GFs, as well as leukocytes. The concentrate is generat-
ed from a blood harvest without any artificial biochemical 
modifications and anticoagulants [10]. Previous research 
has demonstrated that PRF contains a greater amount 
of GFs than PRP. It induces higher fibroblast migration 
and expression of the transforming growth factor-β1, the 
platelet-derived growth factor, and the vascular endothe-
lial growth factor [11]. Along with these factors, there is 
a higher concentration of the fibroblast growth factor, the 
insulin-like growth factor-1, the epidermal growth factor, 
and the platelet-derived epidermal growth factor. Thus, 
they ensure a better environment for regeneration and 
repair of the defects. Currently, PRF is widely utilized in 
the surgical treatment of periodontal intrabony defects, 
treatment of furcation defects, sinus lift procedures, and 
tissue engineering [12].
Since the standard PRF is not entirely appropriate for 
injection, a new injectable formulation of PRF (termed 
I-PRF) enables easier use of the platelet concentrate in a 
liquid state. After being generated during centrifugation, 
it maintains its liquid viscosity for about 15 minutes. [13, 
14]. Initially, the PRF has been developed at high centrifu-
gation speeds, enabling a formation of a fibrin clot, which 
could be utilized as a three-dimensional scaffold for the 
promotion of periodontal regeneration [15].
Generally, the assessment of periodontal therapy con-
sists of a full-mouth periodontal examination, which en-
ables estimation of the degree of tissue inflammation and 
destruction. This is conducted by objective measuring 
of clinical attachment level (CAL), gingival margin level 
(GML), probing pocket depth (PPD), bleeding on probing 
(BOP), plaque index (PI), and radiographs assessing the 
alveolar bone level [16].
So far, patients with CP have not been treated with I-
PRF during SRP treatment. Therefore, the aim of this study 
was to determine the effects of local I-PRF application in 
conjunction with SRP, compared to application of SRP 
alone, on periodontal clinical parameters of CP. 
METHODS
The randomized, split-mouth, controlled clinical trial 
recruited patients with CP from the Department of Peri-
odontology, School of Dental Medicine, University of Bel-
grade. The trial evaluated clinical periodontal outcomes 
after the initial treatment with or without conjunction of 
I-PRF. This trial had been approved by the Ethics Commit-
tee of the Department of Periodontology, School of Dental 
Medicine, University of Belgrade. After being informed 
of the research methods, all the patients submitted their 
written consent for sharing their personal data and their 
participation in the study. The study was registered at Clin-
icalTrials.gov as NCT02898675 on September 12, 2016.
For three months, 30 adult patients were included in 
the study. The preconditions for participating in the study 
were a presence of minimum 3 mm CAL and horizontal 
bone loss of both quadrants of the mandible or maxilla, 
which were confirmed by full-mouth radiograph images. 
The following criteria were used in the patient selection:
–  Inclusion criteria: age of 20–75 years; a minimum of 
six teeth per quadrant; a minimum of two teeth in 
each quadrant with a probing depth ≥5 mm; BOP 
had to be at ≥ 40% tooth sites; no involvement of 
furcation; good general health;
–  Exclusion criteria: periodontal therapy within the last 
12 months; having surgical therapy; use of antibiotics 
over the last six months; ongoing drug therapy that 
might have an impact on the clinical signs and symp-
toms of periodontitis; pregnancy or nursing; current 
and former smokers.
Clinical charting
Clinical charting was performed immediately before the 
first treatment. The following examinations were carried 
out after three months. The research included the exami-
nation of all teeth and tooth sites, except the third molars 
and the tooth sites associated with furcation involvements 
of degree II and III [17]. The following variables were re-
corded from the mesio-buccal, mid-buccal, disto-buccal, 
disto-lingual, mid-lingual, and mesio-lingual surfaces of 
each tooth: CAL, GML, PPD, BOP, and PI.
The examiner, a specialist of periodontology, performed 
and noted all the examinations. Prior to the start of the 
study, the examiner gained the adequate level of compe-
tence and reproducibility skills in accordance with the 
various clinical parameters and indices that were going 
to be utilized [18]. 
Treatment procedures
In regard to screening examination, the patients were 
thoroughly informed on self-performed plaque control 
activities consisting of using the modified Bass brushing 
technique, a soft toothbrush, regular toothpaste twice a 
day, and inter-dental cleaning with inter-dental brushes 
once a day. A full-mouth SRP was conducted in all diseased 
sites by using local anesthesia, in one or two sessions, dur-
ing the period of 24 hours. The standard of oral hygiene 
was checked at the baseline examination and during the 
recall visit after three months following the baseline treat-
ment, and further instructions were provided when it was 
necessary. Three months following the completion of the 
baseline treatment, all the patients were recalled for profes-
sional supragingival plaque control and reinforcement of 
oral hygiene. Additionally, re-instrumentation was con-
ducted by using the ultrasonic device in all the sites with 
a remaining PPD of ≥ 5 mm.
Preparation of I-PRF
Blood samples were taken into two 10 ml tubes and prepared 
for I-PRF preparation. The blood without anticoagulant 
was then centrifuged at 700 rpm for three minutes (60 g) 
at room temperature by a Duo Centrifuge (Process for PRF, 
Nice, France). The upper liquid layer was taken as I-PRF 
by using a syringe. Afterwards, by applying I-PRF into 
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periodontal pockets through perforations at the point of 
interdental space on individually formed occlusal splints, 
it was enabled to hold it there for a longer time. The I-PRF 
was applied in one quadrant (study group) of the chosen 
jaw (mandible or maxilla), whereas the physiological sa-
line was inserted in the opposite side (control group). The 
splint was removed after 15 minutes. Treatment allocation 
was decided by a toss of a coin.
Statistical analysis
Mean values and standard deviation were calculated. 
The Mann–Whitney U-test was performed to determine 
whether the two groups had similar clinical measure-
ments at baseline and whether one treatment produced 
better clinical results after a three-month follow-up. The 
Wilcoxon signed-rank test was used to analyze whether 
clinical measurements differed before and after treatment. 
For the whole statistical analysis, a significance level of 5% 
was used. Software package PASW Statistics Version 18.0 
(SPSS Inc., Chicago, IL, USA) was used for all calculations.
RESULTS
All the patients’ tooth sites did not display any clinical 
signs of deterioration after a three-month period. It proved 
to be uneventful healing, without any pain or any other 
discomfort in either of the treatment modalities. The only 
discomfort was experienced by three patients, due to re-
peated blood collection after failing to find an appropriate 
blood vessel. During the therapy, one patient no longer 
participated in the study since she got pregnant, and anoth-
er one left the country. The remaining 24 subjects, i.e. 10 
men and 14 women, finished the treatment protocol. The 
mean age was 37.29 ± 10.23 years, ranging 22–64 years.
At baseline, none of the assessed clinical parameters 
showed a statistically significant difference between the 
study and control groups (Table 1).
Throughout the study, a significant gain in CAL, GML, 
BOP, PI, and a significant reduction in PPD took place in 
the study group (Table 2), as well as in the control group 
(Table 3).
Three months after the therapy (Table 4), the mean value 
of CAL decreased from 1.97 ± 0.75 (0.25–3.31) to 1.07 ± 0.44 
(0.12–1.78) in the study group, whereas it decreased 
from 1.81 ± 0.66 (0.42–2.96) to 1.48 ± 0.55 (0.22–2.3) 
in the control group. Similarly, the corresponding values 
for GML and PPD showed statistically significant differ-
ence between the groups (p = 0.040 and p = 0.006, respec-
tively). The major difference was recorded with BOP – at 
the baseline examination, 57% of the surfaces in the study 
group and 61% of the surfaces in the control group showed 
BOP. After a three-month period, a marked improvement 
in the bleeding scores took place in both groups, so that 
15% of the PDT group and 33% of the SRP group had 
positive scores (p = 0.00). Initially, PI was 0.61 ± 0.517 and 
0.64 ± 0.19, respectively. After three months, plaque val-
ues were markedly reduced, and no statistically significant 
differences were recorded between plaque scores of sur-
faces treated by both therapy modalities (p = 0.012).
DISCUSSION
Obviously, the initial treatment of CP aims to achieve the 
results that can ensure a long-term improvement in clini-
cally measured parameters. This randomized clinical trial 
with a split-mouth design displayed the difference between 
the effects of SRP in conjunction with I-PRF vs. SRP alone 
Table 1. The mean values of clinical parameters of both groups at 
baseline
Index Study group X ± SD (min–max)
Control group 
X ± SD (min–max)
ap
CAL 1.97 ± 0.75 (0.25–3.31) 1.81 ± 0.66 (0.42–2.96) 0.404
GML 1.72 ± 0.6 (0.02–2.5) 1.86 ± 0.56 (0.75–2.54) 0.457
PPD 3.68 ± 0.72 (1.63–4.53) 3.68 ± 0.89 (1.67–4.96) 0.975
BOP 0.57 ± 0.21 (0.19–0.96) 0.61 ± 0.17 (0.31–0.94) 0.433
PI 0.61 ± 0.517 (0.29–0.92) 0.64 ± 0.19 (0.31–0.91) 0.413
CAL – clinical attachment level; GML – gingival margin level; PPD – probing 
pocket depth; BOP – bleeding on probing; PI – plaque index; 
aMann–Whitney test
Table 2. The mean values of clinical parameters of study group at 
baseline and after three months
Index BaselineX ± SD (min-max)
After 3 months
X ± SD (min-max)
ap
CAL 1.97 ± 0.75 (0.25–3.31) 1.07 ± 0.44 (0.12–1.78) 0.000*
GML 1.72 ± 0.6 (0.02–2.5) 0.62 ± 0.49 (-0.72–1.3) 0.000*
PPD 3.68 ± 0.72 (1.63–4.53) 1.73 ± 0.64 (1.03–2.98) 0.000*
BOP 0.57 ± 0.21 (0.19–0.96) 0.15 ± 0.18 (0–0.9) 0.000*
PI 0.61 ± 0.517 (0.29–0.92) 0.19 ± 0.23 (0–1.15) 0.000*
CAL – clinical attachment level; GML – gingival margin level; PPD – probing 
pocket depth; BOP – bleeding on probing; PI – plaque index; 
aANOVA; 
*statistically significant 
Table 3. The mean values of clinical parameters of both groups after 
three months
Index Study groupX ± SD (min–max)
Control group
X ± SD (min–max)
ap
CAL 1.07 ± 0.44 (0.12–1.78) 1.48 ± 0.55 (0.22–2.3) 0.003*
GML 0.62 ± 0.49 (-0.72–1.3) 0.99 ± 0.57 (0.12–2.1) 0.040*
PPD 1.73 ± 0.64 (1.03–2.98) 2.31 ± 0.73 (1.22–3.58) 0.006*
BOP 0.15 ± 0.18 (0–0.9) 0.33 ± 0.12 (0–0.58) 0.000*
PI 0.19 ± 0.23 (0–1.15) 0.2 ± 0.89 (0.12–0.5) 0.112
CAL – clinical attachment level; GML – gingival margin level; PPD – probing 
pocket depth; BOP – bleeding on probing; PI – plaque index; 
aMann–Whitney test
Table 4. The mean values of clinical parameters of control group at 
baseline and after three months
Index BaselineX ± SD (min–max)
After 3 months 
X ± SD (min–max)
ap
CAL 1.81 ± 0.66 (0.42–2.96) 1.48 ± 0.55 (0.22–2.3) 0.000*
GML 1.86 ± 0.56 (0.75–2.54) 0.99 ± 0.57 (0.12–2.1) 0.000*
PPD 3.68 ± 0.89 (1.67–4.96) 2.31 ± 0.73 (1.22–3.58) 0.000*
BOP 0.61 ± 0.17 (0.31–0.94) 0.33 ± 0.12 (0–0.58) 0.000*
PI 0.64 ± 0.19 (0.31–0.91) 0.20 ± 0.89 (0.12–0.5) 0.000*
CAL – clinical attachment level; GML – gingival margin level; PPD – probing 
pocket depth; BOP – bleeding on probing; PI – plaque index; 
aANOVA; 
*statistically significant 
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in terms of changing clinical periodontal outcomes during 
the initial treatment of CP.
The obtained results demonstrated that both thera-
peutic modalities could result in statistically significant 
improvement of all explored clinical parameters three 
months after initiating the therapy. At baseline, no signifi-
cant differences in terms of PPD and CAL were recorded 
between the two groups. The positive clinical outcomes 
of the control group after three months correspond with 
the previous findings concerning clinical efficacy of SRP 
in treatment of CP. This indicates that in subjects with 
CP, SRP was successful in reducing PPD and improving 
CAL [19]. All the patients were trained to maintain oral 
hygiene regularly. This might have improved the clinical 
parameters in both groups throughout the study period.
Over the years, the conventional therapy of periodon-
titis (SRP) has been enhanced by using various adjunctive 
therapies, mostly by systemically or locally administered 
antibiotics and antiseptics [20]. Since their use involves 
some risk, they should be prescribed only for specific situ-
ations under optimal conditions. Although the influence 
of nonsurgical use of lasers on the initial treatment of CP 
has been considered recently, some studies have shown 
that its impact on PPD and CAL reduction is less effective 
than that of antibiotics [20].
Our research is currently focused on novel adjunctive 
regenerative methods of CP treatment. Although a liquid, 
injectable form of this platelet concentrate was discovered 
in 2006 by Choukroun, only the PRF in the form of fi-
brin membrane was applied during the surgical therapy of 
CP. For the first time, in this study we tried to adequately 
use the injectable form of PRF (I-PRF) for a non-surgical 
treatment of CP. I-PRF is suitable for periodontal pocket 
application due to its advantage of being in a liquid form.
The injectable form of PRF preparation is based on 
a slower and shorter centrifugation spin. Moreover, this 
protocol of centrifugation leads to a higher presence of 
regenerative cells with higher concentration of GFs, and 
cytokines, which together may enhance the healing poten-
tial of both bone and soft tissues [21].
Clinical trials use CAL to examine various therapeutic 
modalities that could either reduce the progression of peri-
odontal disease or enable the regeneration of supporting 
structures. In our study, the progress was made in reducing 
CAL in the test group more than in the control group three 
months after the initial treatment (p < 0.05). The reduction 
matches the previous systematic reviews on SRP with dif-
ferent adjuncts, showing that a three-month therapy leads 
to the CAL value ranging 0.08–1 mm [22, 23]. Our results 
demonstrated CAL gain by es much as 0.9 mm, represent-
ing better outcome compared to the control group with 
only 0.33 mm reduction. CAL gain during SRP with I-PRF 
was far higher when compared to SRP alone. 
The greater clinical value of CAL gain may be due 
to more rapid wound healing, less short-term gingival 
inflammation, and sustained reduction of periopathogenic 
bacteria [24]. A study by Dohan et al. [25] shows that I-
PRF contains more GFs than PRF, which is six to seven 
times more loaded with GFs than PRP. In addition, those 
GFs are released steadily within 21 days [11]. The process 
is enabled due to the fact that after a short period of time, 
approximately 15 minutes, I-PRF is formed into a matrix 
scaffold [11]. The scaffold was proved to have a direct 
impact on the ability of human gingival fibroblasts to mi-
grate, proliferate, release additional GFs and periodontal 
ligament cell growth, as well as to increase the differentia-
tion of osteoblasts [26]. By preventing the down-growth of 
junctional epithelium to the root surfaces and suppressing 
its interference between the root and soft tissue, a new at-
tachment on root surfaces can be formed. 
Furthermore, antimicrobial and anti-inflammatory ef-
fects of PRF have also been described [27]. Dohan et al. 
[28] stated that PRF has immunological and antibacterial 
properties due to its leukocyte degranulation, and possess 
some cytokines that may induce angiogenesis and pro/anti-
inflammatory reactions. The decrease of microorganism 
concentration in this area results in reducing inflamma-
tion. Reducing the inflammation level brings about the 
decrease of PPD, GML, and BOP values. The study of Van 
der Weijden and Timmerman [19] reported the mean PPD 
reductions ranging 1.29–2.16 mm during CP therapy with 
SRP alone. In our research, PPD in the study group was 
reduced by 1.95 mm after a three-month period, while 
the control group showed a significantly lower decrease 
(p < 0.05). At the same time, GML values in the both 
groups were reduced by 1.1 mm and 0.87 mm, respectively.
BOP was also reduced in both groups after three 
months. A successful treatment of CP implies a minimal 
number of sites with BOP (< 10%), with no probing depths 
≤ 3 mm [29]. Our results displayed that BOP after SRP 
alone dropped to 33%, while it decreased to 15% after 
SRP + I-PRF. It is probably due to the presence of residual 
pockets deeper than 4 mm. BOP is proved to be a use-
ful prognostic indicator in estimating periodontal tissue 
after a non-surgical therapy according to sensitivity and 
predictability calculations. This is further documented by 
the fact that presence of residual PPD ≥ 6mm in combi-
nation with BOP ≥ 30% was significantly associated with 
tooth loss [30].
Both groups in our study demonstrated reduced PI after 
three months and the improvement in oral hygiene.
CONCLUSION
Regardless of the limited number of patients, the results 
of the present study indicated that local application of I-
PRF in conjunction with SRP, compared to SRP alone, had 
significant effect on periodontal clinical parameters in the 
treatment of CP. 
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САЖЕТАК
Увод/Циљ Циљ овог истраживања био је да се утврди да 
ли постоји разлика у исходу иницијалне терапије хроничног 
пародонтитиса, на основу клиничких пародонталних пара-
метара после три месеца, применом додатне апликације 
инјектабилног фибрина богатог тромбoцитима.
Методе У студију су укључена двадесет четири болесника 
са хроничним пародонтитисом који имају бар у две регије 
на контралатералним странама вилице дубину сондирања 
већу од 5 mm.
Употребом методе „подељених уста“, болесници су трети-
рани иницијалном терапијом хроничног пародонтитиса у 
комбинацији са инјектабилним фибрином богатим тром-
бoцитима (студијска група) или само иницијалном терапијом 
хроничног пародонтитиса (контролна група). Клинички па-
раметри – ниво припојног епитела, ниво ивице гингиве, ду-
бина сондирања, крварење на провокацију и индекс плака 
бележени су са обе стране.
Резултати У поређењу са почетним мерењима, оба тера-
пијска облика су показала напредак у резултатима. Средња 
вредност нивоа припојног епитела се смањила са 1,97 ± 0,75 
(0,25–3,31) на 1,07 ± 0,44 (0,12–1,78) у студијској групи, док је 
у контролној групи опала са 1,81 ± 0,66 (0,42–2,96) на 1,48 ± 
0,55 (0,22–2,30). Слично томе, одговарајуће вредности нивоа 
ивице гингиве и дубине сондирања показале су статистички 
значајну разлику између група (p = 0,040 и p = 0,0069).
Закључак Без обзира на ограничени број болесника, ини-
цијална терапијa пародонтитиса у комбинацији са инjекта-
билним фибрином богатим тромбоцитима показује значајно 
побољшање клиничких параметара у односу на изоловану 
иницијалну терапију.
Кључне речи: хронични пародонтитис; инјектабилни фи-
брин богат тромбоцитима; иницијална терапија
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